Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

322.44 -3.36 (-1.03%)
Streaming Delayed Price Updated: 1:22 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Insulet Announces Appointment of Robert L. Huffines to its Board of Directors
From Insulet Corporation
Via Business Wire
Insulet to Host Investor Day on November 20, 2025
From Insulet Corporation
Via Business Wire
Insulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New Palette
From Insulet Corporation
Via Business Wire
Insulet Announces CFO Transition
From Insulet Corporation
Via Business Wire
Insulet Elevates Eric Benjamin to Chief Operating Officer
From Insulet Corporation
Via Business Wire
Insulet to Participate in Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
From Insulet Corporation
Via Business Wire
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
From Insulet Corporation
Via Business Wire
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
From Insulet Corporation
Via Business Wire
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Insulet Corporation
Via Business Wire
Insulet Announces Publication of 2024 Sustainability Report
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Appoints Ashley McEvoy President and CEO
From Insulet Corporation
Via Business Wire
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
From Insulet Corporation
Via Business Wire
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
From Insulet Corporation
Via Business Wire
Insulet Announces Pricing of Senior Notes Due 2033
From Insulet Corporation
Via Business Wire
Insulet Announces Proposed Financing Transactions
From Insulet Corporation
Via Business Wire
Insulet Expands Omnipod® 5 to Four More International Markets
From Insulet Corporation
Via Business Wire
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
From Insulet Corporation
Via Business Wire
Insulet to Host Investor Day on June 5, 2025
From Insulet Corporation
Via Business Wire
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
From Insulet Corporation
Via Business Wire
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Insulet Corporation
Via Business Wire
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.